Journal
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA
Volume 44, Issue 2, Pages 193-195Publisher
ELSEVIER INC
DOI: 10.1016/j.jogc.2021.09.015
Keywords
COVID-19; pregnancy outcome; preeclampsia; placenta growth factor
Categories
Ask authors/readers for more resources
COVID-19 infection during pregnancy can present as a preeclampsia-like syndrome, but it can be differentiated and managed appropriately using PlGF testing.
Background: Hypertension, proteinuria, and hepatic dysfunction have been described as manifestations of coronavirus disease 2019 (COVID-19) and are generally accepted as poor prognostic factors. However, these same findings can also occur in pregnant women with preeclampsia, thus creating a diagnostic challenge. Case: We report a case of COVID-19 infection in an otherwise healthy pregnant patient with secondary hypertension, proteinuria, and significant hepatic dysfunction. Maternal placental growth factor (PlGF) testing was used to rule out preeclampsia. The patient received supportive care and improved significantly. She went on to have a spontaneous vaginal term delivery of a healthy male baby. Conclusion: COVID-19 infection in pregnancy may present as preeclampsia-like syndrome. PlGF testing can be used to differentiate preeclampsia from COVID-19 and facilitate appropriate management. (C) 2021 The Society of Obstetricians and Gynaecologists of Canada/La Societe des obstetriciens et gynecologues du Canada. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available